Interferon-γ (IFN-γ) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity — IFN-γ-induced suppressive activity
Authors:
- 1 January 1989
- journal article
- conference paper
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 30 (1) , 57-64
Abstract
Incubation of human lymphocytes with recombinant interleukin-2 (rIL-2) results in the generation of lymphokine-activated killer (LAK) cells capable of lysing a wide variety of tumor cells. The present study was undertaken to examine the effect of recombinant γ interferon (rIFN-γ) on LAK cell cytotoxicity generated from different peripheral blood mononuclear cell (PBMC) subpopulations. When unseparated PBMC were stimulated by rIL-2 and rIFN-γ, the latter induced a transient enhancement after 2 days followed by a suppression of LAK cell cytotoxicity at day 6. Enhancement of LAK cell cytotoxicity was moderate and inconstant, whereas the inhibition was strong and observed with all the donors tested. This suppression was not associated with a decrease in the [3H]thymidine uptake. PBMC depleted of adherent cells were more sensitive to the stimulation by rIL-2 and the induced cytotoxicity was not modified by rIFN-γ. Monocyte-enriched plastic-adherent cells, when incubated with rIL-2 and rIFN-γ, became cytotoxic after 2–3 days of culture and inhibited LAK cell activity after 5–6 days. Collectively, our results suggest that rIFN-γ affects LAK cell cytotoxicity through the activation of plastic-adherent, monocyte-rich, cells which modulate natural killer cells, first in a positive, then in a negative way.Keywords
This publication has 26 references indexed in Scilit:
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Lymphokine-activated killer cell activityImmunology Today, 1987
- Interaction of recombinant interferons with recombinant interleukin-2: Differential effects on natural killer cell activity and interleukin-2-activated killer cellsInternational Journal of Cancer, 1986
- Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated LymphocytesAnnual Review of Immunology, 1986
- Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells.Journal of Experimental Medicine, 1985
- Natural killer-mediated lysis of normal and malignant target cells, and its regulation by monocytes.Journal of Experimental Medicine, 1985
- Monocyte-mediated augmentation of human natural cell-mediated cytotoxicityCellular Immunology, 1985
- Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.Journal of Experimental Medicine, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.Journal of Experimental Medicine, 1982